SEATTLE--(BUSINESS WIRE)--Nov. 1, 2017--
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy
company focused on developing treatments for autoimmune diseases and
cancer, today announced the company will present at two upcoming
investor conferences in November.
Stifel 2017 Healthcare Conference
Tuesday, November 14,
2017, at 3:30 p.m. Eastern Time in New York.
29th Annual Piper Jaffray Healthcare
Conference
Wednesday, November 29, 2017, at 10:50 a.m. Eastern
Time in New York.
A live webcast of each presentation will be available online by visiting
the investor relations page of the Company’s website, at https://ir.alpineimmunesciences.com/events.
An archive of each webcast will be available on the Company’s website
for 30 days.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is focused on developing novel
protein-based immunotherapies using its proprietary Variant Ig Domain
(vIgD) platform technology. The vIgD platform is designed to interact
with multiple targets, including many present in the immune synapse.
Alpine’s vIgDs are developed using a process known as directed
evolution, which produces proteins capable of either enhancing or
diminishing an immune response and thereby may potentially apply
therapeutically to cancer, autoimmune, and inflammatory diseases. Alpine
has also developed Transmembrane Immunomodulatory Protein (TIP)
technology, based on the vIgD platform, to potentially enhance
engineered cellular therapies. For more information visit www.alpineimmunesciences.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171101006252/en/
Source: Alpine Immune Sciences, Inc.
For Alpine Immune Sciences, Inc.
Courtney Dugan, 212-257-6723
[email protected]
